NYSE:AORT Artivion (AORT) Stock Price, News & Analysis $22.25 -0.32 (-1.41%) Closing price 03:59 PM EasternExtended Trading$22.68 +0.42 (+1.91%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Artivion Stock (NYSE:AORT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Artivion alerts:Sign Up Key Stats Today's Range$22.16▼$23.1150-Day Range$22.24▼$38.7552-Week Range$19.16▼$48.25Volume699,045 shsAverage Volume508,898 shsMarket Capitalization$1.08 billionP/E Ratio92.72Dividend YieldN/APrice Target$47.83Consensus RatingModerate Buy Company Overview Artivion, Inc. (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction. Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation. Headquartered in Kennesaw, Georgia, Artivion operates manufacturing and processing facilities in the United States and Europe, with commercial teams serving hospitals and surgical centers across North America, Latin America, Europe, the Middle East and Asia-Pacific. Its global footprint is supported by direct sales operations and distribution partnerships that deliver both off-the-shelf and custom tissue solutions to clinicians worldwide. Leadership at Artivion is focused on expanding the company’s product pipeline through research and development initiatives and strategic acquisitions. Under the direction of CEO Paul F. Le Gars, the company has pursued regulatory approvals across multiple markets and invested in next-generation tissue processing technologies. Through this combination of biologic innovation and device engineering, Artivion aims to address unmet clinical needs in cardiovascular surgery and improve patient outcomes over the long term. AI Generated. May Contain Errors. Read More Artivion Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreAORT MarketRank™: Artivion scored higher than 77% of companies evaluated by MarketBeat, and ranked 176th out of 871 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingArtivion has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialArtivion has a consensus price target of $47.83, representing about 111.2% upside from its current price of $22.65.Amount of Analyst CoverageArtivion has only been the subject of 4 research reports in the past 90 days.Read more about Artivion's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth50.00% Earnings GrowthEarnings for Artivion are expected to grow by 50.00% in the coming year, from $0.50 to $0.75 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Artivion is 94.38, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.18.Price to Earnings Ratio vs. SectorThe P/E ratio of Artivion is 94.38, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.28.Price to Book Value per Share RatioArtivion has a P/B Ratio of 2.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Artivion's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.27% of the float of Artivion has been sold short.Short Interest Ratio / Days to CoverArtivion has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Artivion has recently increased by 1.11%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArtivion does not currently pay a dividend.Dividend GrowthArtivion does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A Search Interest2 people have searched for AORT on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Artivion to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Artivion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,722,655.00 in company stock.Percentage Held by Insiders6.30% of the stock of Artivion is held by insiders.Percentage Held by Institutions86.37% of the stock of Artivion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Artivion's insider trading history. Receive AORT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artivion and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AORT Stock News HeadlinesArtivion (NYSE:AORT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfMay 20, 2026 | finance.yahoo.comComparing SiBone (NASDAQ:SIBN) & Artivion (NYSE:AORT)May 20, 2026 | americanbankingnews.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.May 29 at 1:00 AM | Profits Run (Ad)Artivion Bets On Full Aortic Arch Suite After Endospan DealMay 19, 2026 | finance.yahoo.comArtivion, Inc.: Artivion Completes Acquisition of Endospan Ltd.May 18, 2026 | finanznachrichten.deCrafting title options within editorial guidelines An ETF Shop Just Made a Beaten-Down Medtech Its Top HoldingMay 18, 2026 | fool.comArtivion strengthens aortic arch portfolio with $135m Endospan acquisitionMay 18, 2026 | msn.comEndospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch SystemMay 18, 2026 | financialpost.comFSee More Headlines AORT Stock Analysis - Frequently Asked Questions How have AORT shares performed this year? Artivion's stock was trading at $45.71 on January 1st, 2026. Since then, AORT shares have decreased by 50.4% and is now trading at $22.65. How were Artivion's earnings last quarter? Artivion, Inc. (NYSE:AORT) posted its quarterly earnings data on Thursday, February, 12th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.14 by $0.03. Artivion's revenue for the quarter was up 19.2% on a year-over-year basis. Read the conference call transcript. Who are Artivion's major shareholders? Artivion's top institutional shareholders include Conestoga Capital Advisors LLC (2.42%), Dimensional Fund Advisors LP (2.12%), Bank of America Corp DE (1.08%) and Peregrine Capital Management LLC (0.71%). Insiders that own company stock include James P Mackin, John E Davis, Lance A Berry, Jean F Holloway, Amy Horton, Marshall S Stanton, Rochelle L Maney, Dennis B Maier, Matthew A Getz, Andrew M Green, Anthony B Semedo and Elizabeth A Hoff. View institutional ownership trends. How do I buy shares of Artivion? Shares of AORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Artivion own? Based on aggregate information from My MarketBeat watchlists, some other companies that Artivion investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST). Company Calendar Last Earnings2/12/2026Today5/29/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 AORT's financial health is in the Red zone, according to TradeSmith. AORT has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNYSE:AORT CIK784199 Webwww.cryolife.com Phone(770) 419-3355Fax770-426-0031Employees1,800Year Founded1984Price Target and Rating Average Price Target for Artivion$47.83 High Price Target$55.00 Low Price Target$42.00 Potential Upside/Downside+115.0%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)$0.24 Trailing P/E Ratio92.72 Forward P/E Ratio44.50 P/E GrowthN/ANet Income$9.77 million Net Margins2.55% Pretax Margin3.80% Return on Equity7.15% Return on Assets3.63% Debt Debt-to-Equity Ratio0.48 Current Ratio3.86 Quick Ratio2.80 Sales & Book Value Annual Sales$441.33 million Price / Sales2.45 Cash Flow$1.08 per share Price / Cash Flow20.66 Book Value$9.28 per share Price / Book2.40Miscellaneous Outstanding Shares48,540,000Free Float45,485,000Market Cap$1.08 billion OptionableOptionable Beta1.41 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NYSE:AORT) was last updated on 5/29/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artivion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artivion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
